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Abstract: Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related death
since most patients are diagnosed at advanced stage and the current systemic treatment options
using molecular-targeted drugs remain unsatisfactory. However, the recent success of cancer
immunotherapies has revolutionized the landscape of cancer therapy. Since HCC is characterized by
metachronous multicentric occurrence, immunotherapies that induce systemic and durable responses
could be an appealing treatment option. Despite the suppressive milieu of the liver and tumor
immunosurveillance escape mechanisms, clinical studies of checkpoint inhibitors in patients with
advanced HCC have yielded promising results. Here, we provide an update on recent advances in
HCC immunotherapies. First, we describe the unique tolerogenic properties of hepatic immunity and
its interaction with HCC and then review the status of already or nearly available immune checkpoint
blockade-based therapies as well as other immunotherapy strategies at the preclinical or clinical
trial stage.
Keywords: hepatocellular carcinoma; immunotherapy; immune checkpoint inhibitor; PD-1; CTLA-4;
combination therapy
1. Introduction
Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer and poses a
serious health problem worldwide [1]. Although various surveillance systems and treatment strategies
have been developed and are recommended by guidelines, including surgical resection, radiofrequency
ablation (RFA), transarterial chemoembolization (TACE), systemic therapy, and liver transplantation,
the prognosis of HCC remains poor due to high levels of high intra- and extra-hepatic recurrence and
metastasis [2,3]. Systemic therapies using molecular-targeted agents (MTAs) have been considered
efficient and are recommended for patients with advanced-stage HCC [2,4]; however, the regimens
currently available are often unsatisfactory. Therefore, a novel approach that uses a different mechanism
to these conventional therapies is required to improve the prognosis of HCC.
The recent development of cancer immunotherapies using immune checkpoint inhibitors (ICIs)
targeting cytotoxic T-lymphocyte-associated protein-4 (CTLA-4) and anti-programmed cell death
protein-1 (PD-1) has dramatically changed the landscape of cancer therapy and was awarded the
Nobel Prize in 2018. Several monoclonal antibodies (mAbs) targeting CTLA-4, PD-1, or its ligand
programmed cell death-ligand 1 (PD-L1) have now been approved by the FDA for various types of
cancers [5]. The liver is a tolerogenic organ [6] that is relevant to successful allograft acceptance after
transplantation. Thus, the development of antitumor immunity against HCC might be speculated to
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be synergistically impeded by this tolerogenic nature of the liver and the immunosuppressive tumor
microenvironment of HCC. However, the potential of cancer immunotherapy to induce systemic
and durable antitumor responses may make it an ideal therapeutic option for HCC characterized
by metachronous multicentric occurrence. Indeed, several ICI therapies targeting PD-1/PD-L1 and
CTLA-4 have already demonstrated promising activity against HCC and manageable safety in clinical
trials, thus have been approved by the FDA. Combination ICI-based strategies have also shown
promising results, while other classes of immunotherapies have begun to emerge and are being tested
in preclinical and clinical studies.
In this review, we first provide an overview of the unique intrinsic immunotolerant environment
of the liver and the immune evasion mechanisms of HCC, and then review recent advances in different
immunotherapy approaches and their combinations for treating HCC.
2. Tolerogenic Liver Immune Environment and HCC Immune Evasion Mechanisms
The liver is a tolerogenic organ in which a unique immune environment prevents the overactivation
of the immune system to antigens derived from food and bacterial products in the portal flow [6].
Immune tolerance in the liver is induced by non-parenchymal cells. Kupffer cells (KCs) are liver-resident
macrophages that play a role in pathogen clearance mediated by innate immune activation [7].
However, under physiological conditions, KCs induce tolerance by impairing T cell activation or
preferentially expanding regulatory T cells (Tregs) by secreting immunosuppressive factors such
as IL-10, TGF- β, and prostaglandin E2 [8,9]. Liver sinusoidal endothelial cells (LSECs), which act
as antigen-presenting cells (APCs) and form a cellular barrier between the liver parenchyma and
sinusoid [10], are characterized by low co-stimulatory molecule levels, high immune checkpoint
molecule levels, and immunosuppressive cytokine production, all of which impede their potential
for T cell activation and induce immune tolerance [11,12]. Hepatic dendritic cells (DCs) mediate
the induction of T cell tolerance rather than their activation [13], presumably, as they are under the
influence of IL-10 and TGF-β secreted by KCs and LSECs [14]. In addition to these non-parenchymal
cells, hepatocytes also function as APCs by directly interacting with and presenting antigens to naïve
T cells; however, hepatocytes predispose T cells towards tolerance because they lack co-stimulatory
molecule expression [15]. Together, these immunosuppressive features of the liver might impede the
development of antitumor immunity.
HCC evades host immunosurveillance via multiple mechanisms; for instance, HCC cells silence the
expression of tumor antigens or antigen presentation-related molecules so that cytotoxic T cells (CTLs)
cannot recognize tumor cells [16,17]. HCC cells also escape immunosurveillance by expressing immune
checkpoint molecules such as PD-L1 and producing various immunoinhibitory molecules, including
TGF-β, IL-10, indoleamine 2, 3-dioxygenase, arginase, and adenosine [18,19]. Immunosuppressive
stromal cells are also a critical component of immune dysregulation. Myeloid-derived suppressor
cells (MDSCs) are a heterogeneous population of immature myeloid cells that inhibit T cell activation
via iNOS, ROS, and increased arginase activity, and induce Treg expansion by producing IL-10 and
TGF-β [20]. Moreover, the frequency of MDSCs in HCC patients has been reported to correlate
with tumor progression [21]. Macrophages are generally categorized as having an M1 or M2 state;
M1 macrophages display an antitumor phenotype by producing high and low levels of IL-12 and
IL-10, respectively, whereas M2 macrophages exhibit a tumor supportive phenotype with opposite
cytokine profiles. During HCC progression, hepatic macrophages are skewed from an M1 phenotype
to an M2 phenotype characteristic of tumor-associated macrophages (TAMs), which act as immune
suppressor cells and support tumor growth by promoting angiogenesis and tumor invasion [22].
Tregs can also impede immune surveillance against HCC due to their immunosuppressive functions;
indeed, they have been shown to densely infiltrate the tumor site in patients with HCC, with the
number of intratumoral Tregs acting as an independent prognostic factor of overall survival (OS) and
disease-free survival (DFS) in those patients [23].
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Even under these immunosuppressive conditions, several studies have shown that antitumor
immunity exists in patients with HCC. For instance, T cells specific for four different tumor-associated
antigens (TAAs) were detected in both the tumor tissue and peripheral blood of patients with
HCC, with the breadth of T cell response correlating with survival [24]. Another study found that
the intratumoral density of activated CTLs in patients with HCC after resection was associated
with OS and that the intratumoral balance between CTLs and Tregs was associated with OS and
DFS [25]. These observations suggest that the immunogenic potential of HCC could be controlled by
optimized immunotherapy.
3. PD-1/PD-L1 and CTLA-4-Blockade Therapies
3.1. Basic Immunobiology of PD-1 and CTLA-4
Immune checkpoint molecules—among which, PD-1 and CTLA-4 are the best studied—play
essential roles in preventing T cell overactivation by interacting with APCs and other cell types. PD-1 is
a member of the CD28 family that is expressed on activated T cells, B cells, and myeloid cells and
negatively regulates the immune system. The engagement of PD-1 by its ligand PD-L1 leads to the
transmission of suppressive signals into T cells and the induction of peripheral tolerance [26]. In the
liver, PD-L1 is constitutively expressed on liver non-parenchymal cells such as LSECs and KCs [27];
however, PD-L1 is aberrantly expressed in various tumors, including HCC tumor cells, allowing
them to escape from host immune surveillance. Indeed, it has been demonstrated that tumor PD-L1
expression is associated with HCC prognosis after curative surgical treatment, suggesting that the
PD-1/PD-L1 pathway is an immune escape mechanism in HCC [19]. Another member of the CD28
family, CTLA-4, is induced on naïve T cells by antigen activation but is constitutively expressed on
Tregs [28]. CTLA-4 binds to CD80 and CD86 more tightly than CD28, which provides a positive
signal required for T cell activation; therefore, CTLA-4 induces peripheral tolerance by counteracting
CD28-mediated costimulatory signals [28]. Importantly, the expression of CTLA-4 on Tregs depletes
APCs of CD80 and CD86, leaving them with a reduced ability to prime naïve T cells [28]. The intensive
study of PD-1- and CTLA-4-mediated immunosuppression culminated in the dramatic success of
cancer immunotherapies [29] and many clinical trials of ICI mono- and combination therapies targeting
PD-1/PD-L1 and CTLA-4 in HCC have now been conducted.
3.2. ICI Monotherapies Directed Against PD-1 and CTLA-4
Many clinical trials have been conducted for ICI monotherapies in HCC (Table 1) and the first
to be approved by the FDA was the anti-PD-1 mAb nivolumab. A phase I/II trial of nivolumab in
patients with advanced HCC (CheckMate-040) showed promising results. In the dose-expansion phase
in which a total of 214 patients in 4 cohorts were enrolled, the objective response rate (ORR) was
20%, the disease control rate (DCR) was 64%, and progression free survival (PFS) was 4.1 months [30].
Since adverse events (AEs) were fairly mild [30], nivolumab was approved by the FDA in September
2017 as a second-line treatment for unresectable HCC after sorafenib failure, based on subgroup
analysis in CheckMate-040 [4]. However, a phase III trial (CheckMate-459) evaluating nivolumab
versus sorafenib as first-line treatments in patients with unresectable HCC revealed that the trial did
not achieve statistical significance for its primary OS endpoint as per the prespecified analysis [31].
The CheckMate-9DX trial is currently evaluating adjuvant nivolumab versus a placebo in HCC patients
at high risk of recurrence after curative hepatic resection or ablation.
Pembrolizumab is another anti-PD-1 mAb that was granted accelerated approval by the FDA
in May 2017 for patients with unresectable or metastatic microsatellite instability-high (MSI-H) or
mismatch repair deficient (dMMR) solid tumors that continued to progress after conventional treatment,
based on the data from five clinical trials [32]. A phase II trial (KEYNOTE-224) revealed the potential
of pembrolizumab against HCC after sorafenib failure, with an ORR of 17% with one complete
response (CR), a DCR of 61%, and AEs (>grade 3) reported in 26% of patients [33]. Based on this data,
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pembrolizumab was granted accelerated approval by the FDA in November 2018 as a second-line
treatment after sorafenib. A phase III trial (KEYNOTE-240) comparing pembrolizumab to a placebo as
a second-line treatment demonstrated that pembrolizumab was associated with a longer median OS
and PFS; however, these findings were not deemed statistically significant according to the prespecified
statistical plan [34]. Two further phase III trials are currently ongoing: KEYNOTE-394 is evaluating
pembrolizumab versus a placebo and best supportive care in Asian patients with systemically treated
advanced HCC, while KEYNOTE-937 is evaluating pembrolizumab versus a placebo as an adjuvant
therapy in HCC patients after curative treatment.
In addition, the anti-PD-L1 mAb Durvalumab was tested in a phase I/II trial (NCT01693562)
of patients with advanced HCC who had been previously treated with sorafenib, achieving an OS
rate of 10.3% in 39 patients [35]. The investigational IgG4 anti-PD-1 Ab, tislelizumab (BGB-A317),
was designed to bind minimally to FcγR on macrophages in order to abrogate antibody-dependent
phagocytosis, which is a potential mechanism of anti-PD-1 therapy resistance. Tislelizumab has
demonstrated a good preliminary safety profile and antitumor activity in a phase I trial and a phase
III trial (RATIONALE 301) of tislelizumab versus sorafenib as a first-line treatment in patients with
unresectable HCC is currently underway [36].
The anti-CTLA-4 mAb, tremelimumab, has been tested in a small phase II pilot trial (NCT01008358)
of HCV-infected patients with advanced HCC, demonstrating partial response (PR) and stable disease
(SD) rates of 17.6 and 58.8%, respectively. Moreover, the treatment was well tolerated, and no patients
needed steroids due to severe immune-related AEs (irAEs) [37].
Table 1. Summary of clinical trials of ICI monotherapy for HCC.








vs. Sorafenib III 743 Naïve
15% vs.




vs. Placebo III 530 Adjuvant N/A N/A N/A N/A
NCT02702414




















vs. Sorafenib III N/A Naïve N/A N/A N/A N/A
NCT01693562 [35] PD-L1 Durvalumab I/II 39 Pre-treated 10.3% 33.3% NA 13.2
NCT01008358 [37] CTLA-4 Tremelimumab II 20 Pre-treated 17.6% 76.4% 6.48 8.2
N, number of patients; N/A; not available; NR, not reached; * dose-expansion phase.
4. ICI-Based Combination Therapy
Although ICI monotherapy regimens have shown benefits in some HCC patients with generally
acceptable AE profiles, their response rates (approximately 20%) have been unsatisfactory, presumably
due to the immunosuppressive properties of the liver and HCC tumor microenvironment. To achieve
enhanced therapeutic efficacy, several types of combination strategy are currently being explored
(Table 2).
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Table 2. Summary of clinical trials of ICI combination therapy for HCC.
Trial Identifier Target Drugs Phase N Patient Group ORR DCR PFS (Median, mo) OS (Median, mo)
ICI + ICI
NCT01658878
(CheckMate040) [38] PD-1 + CTLA-4
Nivolumab +
Ipilumumab II 148 Pre-treated
31%
(5%CR) 49.0% NA 22.8 (arm A)
NCT04039607




III 1084 Naïve N/A N/A N/A N/A
NCT02519348 [39] PD-L1 + CTLA-4 Durvalumab +Tremelimumab I/II 40 Naive/Pre-treated 15.0%
57.5%
at 4 mo NA NA
NCT03298451




III 1310 Naïve N/A N/A N/A N/A
ICI +MTA
NCT03006926
(KEYNOTE-524) [40] PD-1 + MTA
Pembrolizumab +
Lenvatinib Ib 30 Naive 36.7% 90.0% 9.7 (TTP) 14.6
NCT03713593




III 750 Naïve N/A N/A N/A N/A
NCT03434379








NA 6.8 vs.4.3 NR vs. 13.2
NCT04102098




III 662 Adjuvant N/A N/A N/A N/A
NCT03847428




III 888 Adjuvant N/A N/A N/A N/A
NCT03764293 PD-1 + MTA SHR-1210 + Apatinibvs. Sorafenib III 510 Naive N/A N/A N/A N/A
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Table 2. Cont.
Trial Identifier Target Drugs Phase N Patient Group ORR DCR PFS (Median, mo) OS (Median, mo)
ICI +MTA
NCT03755791




III 740 Naive N/A N/A N/A N/A
NCT03794440













III 448 Naive N/A N/A N/A N/A
ICI + ablation








III 600 Locoregional(Naïve)N/A N/A N/A N/A
ICI + Radiation
NCT03316872 PD-1 + Radiation Pembrolizumab +Radiation (SBRT) II 30 Pre-treated N/A N/A N/A N/A
NCT03099564 PD-1 +radioembolization
Pembrolizumab + Y90
radioembolization I 30 Locoregional N/A N/A N/A N/A
NCT03033446 PD-1 +radioembolization
Nivolumab + Y90
radioembolization II 40 Advanced N/A N/A N/A N/A
MTA, molecular-targeted agent; SBRT, stereotactic body radiotherapy; TACE, transarterial chemoembolization; Y90, Yttrium-90; Apatinib, VEGFR2 inhibitor; Cabozantinib, multi kinase
inhibitors of MET, VEGFR2, FLT3, c-KIT and RET; N, number of patients; N/A, not available; NR, not reached.
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4.1. Combination of ICIs with Other ICIs or Immunostimulatory Agents
Anti-PD-1/PD-L1 and anti-CTLA-4 mAb combination strategies have been evaluated in various
types of cancers. In November 2019, the FDA granted breakthrough therapy designation for
nivolumab in combination with the anti-CTLA-4 inhibitor ipilimumab for patients with advanced
HCC who had previously been treated with sorafenib based on data from the phase I/II CheckMate-040
study of nivolumab plus ipilimumab [38]. The study demonstrated that nivolumab + ipilimumab
achieved clinically meaningful responses and had an acceptable safety profile compared to nivolumab
monotherapy (ORR: 31% and 14%, respectively), with a median OS of 22.8 months in the nivolumab
+ ipilimumab group. Another trial (CheckMate-9DW) evaluating nivolumab + ipilimumab versus
standard care (sorafenib or lenvatinib) in patients with advanced HCC who have received no prior
systemic therapy is currently ongoing.
Durvalumab + tremelimumab has been evaluated in a phase I/II study of patients with advanced
HCC, with an ORR of 17.5% and 7/40 evaluable patients showing PR [39]. The combination was well
tolerated and showed no unexpected safety signals; therefore, a randomized phase III HIMALAYA
study is currently evaluating the efficacy and safety of the durvalumab + tremelimumab combination
and durvalumab monotherapy versus sorafenib as a first-line treatment for patients with unresectable
HCC and no prior systemic therapy. In January 2020, the FDA granted durvalumab + tremelimumab
orphan drug designation for treating patients with HCC.
Other immune checkpoint molecules, such as LAG3 and TIM-3, can also be targeted and combined
with PD-1/PD-L1 or CTLA-4 blockade. For instance, phase I basket trials are currently evaluating the
dual immune checkpoint blockade of LAG-3 and PD-1 (NCT03005782) and dual TIM-3 and PD-L1
blockade (NCT03099109) in patients with HCC. In addition, combination strategies involving agonistic
antibodies that target costimulatory molecules such as 4-1BB, CD40, and OX40 appear to be promising.
In a preclinical study, triple combination therapies targeting 4-1BB, OX40, and PD-L1 demonstrated
prolonged survival in HCC-bearing mice, providing proof of concept for this combination [44]. A phase
I/II basket trial is underway to evaluate the combination of agonistic anti-OX40 Abs with nivolumab
and ipilimumab in patients with HCC (NCT03241173).
4.2. Combination of ICI and Non-Immunological Systemic Therapies
Several clinical trials are currently investigating combinations of ICIs and molecular-targeted therapies.
For instance, anti-VEGF therapy has been demonstrated to not only normalize immunosuppressive tumor
vasculature but also activate DCs and decrease Tregs and MDSCs [45]. In addition, a recent study
demonstrated that anti-VEGF therapy rescues effector T cells from exhaustion by downregulating the
transcription factor TOX [46]. Therefore, anti-VEGF therapies utilizing multi tyrosine kinase inhibitors
(lenvatinib) or anti-VEGFR monoclonal antibodies (bevacizumab) appear to be quite promising in
combination with ICIs.
In July 2019, the FDA granted breakthrough therapy designation for pembrolizumab in
combination with lenvatinib for the first-line treatment of patients with unresectable HCC who
are amenable to locoregional treatment, based on the results of a phase Ib trial (KEYNOTE-524) [40].
Consequently, a phase III trial (LEAP-002) evaluating lenvatinib + pembrolizumab vs. lenvatinib +
placebo as a first-line therapy for advanced HCC is currently ongoing [41]. Recently, the results of
a phase III trial (IMbrave 150) evaluating the anti-PD-L1 mAb atezolizumab + bevacizumab versus
sorafenib monotherapy for patients with unresectable HCC without prior systemic therapy were
presented at ESMO Asia Congress 2019, revealing that the atezolizumab + bevacizumab combination
significantly improved OS and PFS compared to sorafenib [42]. Another phase III study (IMbrave
050) is currently comparing the same combination with active surveillance in HCC patients at high
risk of recurrence after curative treatment, while a phase III trial (EMERALD-2) is also evaluating
the durvalumab + bevacizumab combination or durvalumab alone in the same adjuvant setting.
Several phase III trials are also evaluating other combinations of ICIs and MTAs: SHR-1210 + apatinib
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(NCT03764293), atezolizumab + cabozantinib (NCT03755791/COSMIC-312), and sintilimab (anti-PD-1)
+ bevacizumab biosimilar (NCT03794440/ORIENT-32).
Chemotherapeutic drugs are generally considered to be immunosuppressive agents due to their
toxicity against immune cells; however, they may also be a promising partner to ICIs as they cause
immunogenic cell death, allowing the release of tumor antigens and danger-associated molecular
patterns from the dead tumor and enhancing the immune response [47]. In addition, some anticancer
drugs downregulate Tregs and MDSCs, further promoting tumor eradication [48]. Therefore, a phase
III trial evaluating SHR-1210 (anti-PD-1 Ab) + FOLFOX4 as first-line therapy in patients with advanced
HCC is currently underway (NCT03605706).
4.3. Combination of ICIs and Non-Immunological Locoregional Therapies
Standard locoregional therapies for HCC can trigger effector T cell responses via the release of
tumor-specific antigens from dead tumor cells; therefore, the combined use of locoregional therapies
such as RFA, TACE, and radiation could improve the effectiveness of immunotherapies against HCC.
The combination of tremelimumab + RFA was tested in a phase I/II trial (NCT01853618) of patients
with advanced HCC, with PR and SD noted in five (26%) and 12 (63%) of the 19 evaluable patients,
with a median time to progression (TTP) and OS of 7.4 and 12.3 months, respectively. Moreover,
pathological evaluation revealed that the accumulation of intratumoral CD8+ T cells in patients had a
clinical benefit [43]. TACE has been suggested to exert immunostimulatory effects as the number of
α-fetoprotein (AFP)-specific T cells was observed to increase after TACE [49]. Therefore, a phase III
trial (EMERALD-1) is currently evaluating TACE in combination with durvalumab and bevacizumab
in patients with multiple HCCs (NCT03778957). Radiation with dual checkpoint blockade reportedly
induces optimal responses in melanoma, with a previous preclinical study of melanoma demonstrating
that anti-CTLA-4 increases the CTL:Treg ratio while anti-PD-L1 rescues T cell exhaustion. Moreover,
radiation expanded the T cell receptor (TCR) repertoire, thereby enhancing the antitumor activity
of dual checkpoint blockade [50]. Thus, these results provide proof of concept for combining ICIs
and radiation to treat HCC and phase II trials are currently underway to evaluate pembrolizumab in
combination with stereotactic body radiation therapy (SBRT) (NCT03316872) or Y90 (NCT03099564),
and nivolumab with Y90 (NCT03033446) to treat HCC.
5. Exploring ICI Biomarkers
Considering the success of ICIs, it is necessary to identify predictive biomarkers for patients that
will respond better to ICIs, particularly since PD-L1 expression on tumor cells does not correlate with the
response to anti-PD1 therapy in patients with HCC [30]. MSI, the result of dMMR, was the first predictive
biomarker for PD-1 inhibitors to be approved by the FDA [51]. MSI-H colon cancers display favorable
responses to ICIs; however, MSI-H appears to be a rare event in HCC [52]. Recently, next-generation
sequencing has identified Wnt/CTNNB1 mutations as possible biomarkers for predicting ICI resistance
in patients with advanced HCC; however, next-generation sequencing is too complex and costly to use
in clinical practice [53]. Therefore, the development of clinically and economically feasible biomarkers
is a crucial yet unmet requirement in this field.
6. Non-ICI Immunotherapies
While ICIs release the brake on cancer immunity to unleash dysfunctional antitumor CTLs,
there are other “active” immunotherapies that accelerate cancer immunity, such as cancer vaccines,
oncolytic virotherapy, and cell-based therapy.
6.1. Cancer Vaccines
The two main cancer vaccine strategies are DC vaccines and peptide vaccines. DCs are potent
APCs that can promote tumor-specific T cell responses. In DC vaccines, DCs are loaded with tumor
antigens ex vivo and administered to patients as a cellular vaccine. In a preclinical mouse model,
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DC vaccines pulsed with tumor cell lysate effectively eradicated tumors and displayed histological
evidence of intratumoral lymphocyte infiltration [54]. Unfortunately, clinical trials using DCs pulsed
with tumor antigen peptides [55] or tumor cell lysate [56,57] have only demonstrated marginal activity
in patients with advanced HCC thus far.
Peptide vaccines for HCC utilize shared TAAs, including AFP, glypican-3 (GPC3), and telomerase
reverse transcriptase (TERT). A phase I trial of an AFP-derived peptide vaccine in 15 patients with
HCC found that the vaccine was well tolerated, with CR in one patient (AFP-specific CTL response)
and SD in eight patients [58]. GPC3 is another antigen that is highly expressed in HCC. In a phase I
trial of 33 patients, the GPC3 peptide vaccine was well tolerated with one patient showing PR and
19 showing SD. Importantly, the GPC3 peptide vaccine induced a GPC3-specific CTL response which
correlated with OS. [59]. The same group later demonstrated that PD-1 blockade augmented the
efficacy of the GPC3 vaccine by increasing the number of vaccine-induced CTLs [60]. A phase II trial
of a TERT-derived peptide vaccine (GV1001) in combination with low dose cyclophosphamide showed
no effective antitumor response or prolonged TTP [61]. Overall, low-level clinical responses have been
observed for DC- and TAA-based peptide vaccines so far; therefore, further trials should examine their
combination with immunotherapy.
Neoantigen vaccines are a new cancer vaccine strategy that utilizes tumor neoantigens, which are
the products of non-synonymous tumor-specific mutations and are expected to be an ideal therapeutic
vaccine as they can achieve a full personalization. First, tumor mutations are analyzed by
next-generation sequencing and then candidate neoantigen peptides are predicted on the basis
of HLA-binding algorithms [62]. Results from phase I clinical trials testing neoantigen vaccine in
advanced melanoma are quite encouraging [63,64]. The cancer vaccine development for hepatocellular
carcinoma (HEPAVAC) project, which aims to produce “off-the-shelf” shared antigen-based vaccines
for HCC, also includes the actively personalized vaccine (APVAC) protocol based on patient-specific
neoantigens [65].
6.2. Oncolytic Virotherapy
Oncolytic virotherapy is a novel approach for cancer immunotherapy [66] that utilizes JX-594
(also known as Pexa-Vec), a vaccinia virus designed to preferentially replicate in and lyse tumor cells,
thereby causing the release of antigens from the dead tumor cells and triggering antitumor immunity.
This antitumor immunity can be further stimulated by inserting the human granulocyte-macrophage
colony stimulating factor transgene into JX-594 [67], with a phase I trial showing that JX-594 has a
good safety profile in patients with primary or metastatic liver cancer [68]. A randomized phase
II trial has also been conducted to evaluate the safety and antitumor efficacy of JX-594 in patients
with advanced HCC, finding that intratumoral JX-594 injection was well tolerated at both low and
high doses. Moreover, tumor regression was observed in injected and non-injected tumors, with
one CR and three PRs, and OS was significantly longer in patients that received the high dose than
the low dose (median 14.1 and 6.7 months, respectively) [69]. A randomized open label phase III
trial comparing sorafenib alone and JX-594 + sorafenib in patients with advanced HCC is currently
underway (NCT02562755).
6.3. Cell-Based Immunotherapy
Cell-based immunotherapy, also known as adoptive cell transfer (ACT), is also a promising strategy
that has been explored extensively. For HCC, cytokine-induced killer cells (CIKs), TCR-engineered T
cells, and chimeric antigen receptor T cells (CAR-T) are the major strategies. CIKs are a mixture of
heterogeneous immune cells generated by the ex vivo expansion of peripheral blood mononuclear cells
in the presence of IL-2, IFN-γ, and anti-CD3 mAbs. CIKs consist of NKT cells, NK cells, and CTLs [70]
and display strong cytolytic activity against tumor cells independently of MHC restriction [70].
A randomized phase II trial in treatment-naïve patients with HCC demonstrated that CIK therapy
prolonged OS and PFS [71], while a multicenter open-label randomized phase III trial in patients with
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HCC after curative treatment demonstrated that CIK therapy prolonged recurrence-free survival and
OS [72].
TCR-engineered T cells are generated by integrating cloned tumor antigen-specific TCR into T cells,
circumventing the technical difficulties of TIL therapy wherein TILs must be isolated from tumor tissue
and expanded ex vivo before being infused back into patients. In mouse models, TCR-engineered T
cells recognizing AFP and GPC3 have been reported to control liver tumor growth [73,74], while phase
I trials are currently evaluating genetically modified T cells expressing AFP-specific TCRs in patients
with advanced HCC (NCT03132792) and autologous TCR-engineered T cell therapy targeting MAGEA1
in solid tumors such as HCC (NCT03441100).
The essential structure of CARs consists of an extracellular single-chain antibody domain that
recognizes tumor antigens and an intracellular domain that transmits activation and proliferation
signals into cells [75]. Antigen recognition allows CAR-T cells to eliminate cancer cells in an
MHC restriction-independent manner, thus solving the problem of tumor immune escape via MHC
downregulation [75]. In xenograft mouse models, CAR-T cells targeting GPC3 have been shown to
eradicate GPC3-positive HCC [76], while a phase I trial of anti-GPC3 CAR-T cells with or without
lymphodepletion treatment has been conducted in six patients with relapsed or refractory GPC3
positive HCC. PR and SD were observed in one and three patients, respectively, with no dose-limiting
toxicity identified and only one serious AE of grade 3 fever was reported [77]. In addition, early clinical
trials are currently examining CAR-T cells targeting AFP (NCT03349255), MUC-1 (NCT03198546),
and EpCAM (NCT03013712).
7. Conclusions
HCC is a serious global health problem because current regimens have limited efficacy in HCC
patients, particularly at an advanced disease stage. Cancer immunotherapy has been a significant
breakthrough in cancer treatment in recent years and there has been growing interest regarding
its application in HCC. As reviewed here, several classes of immunotherapy have emerged for
HCC—among which, ICIs targeting PD-1/PD-L1 and CTLA4 hold the greatest promise. However, many
studies evaluating ICI-based therapies and other therapeutic strategies are in progress. There are positive
and negative factors that should be taken into account for developing successful immunotherapy for
HCC (Table 3). Most importantly, it should be designed to counteract the unique immunosuppressive
environment of the liver itself in addition to HCC. Therefore, a deeper understanding of the mechanisms
underlying HCC immunology will allow the rational design of optimal therapies that coordinate the
activation of both innate and adaptive immunity. Research efforts should also be directed toward
identifying predictive biomarkers to avoid inappropriate treatment or overtreatment, particularly since
current immunotherapies can display limited efficacy in a minority of patients, serious irAEs, and high
financial cost.
Table 3. Positive and negative factors for developing successful immunotherapy for HCC.
Positive factors Negative Factors
1
Immunotherapy can induce not only systemic but
also durable responses by immunological memory,
both of which are advantageous for controlling HCC
that is characterized by metachronous multicentric
occurrence.
1 Paucity of biomarkers predictingresponders and non-responders.
2
The presence of tumor-infiltrating lymphocytes
(TILs) in HCC suggests the potential of hosts to
induce endogenous tumor immunity.
2
Tolerogenic nature of hepatic
immunity and immunosuppressive
tumor microenvironment of HCC.
3 Several ICIs have already demonstrated manageablesafety and promising activity in clinical trials. 3
Response rates of ICI monotherapy
are not satisfactory.
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